{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:25:34Z","timestamp":1791912334993,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Foundation\u2013Flanders"},{"DOI":"10.13039\/100001491","name":"Belgian American Educational Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["N\u00ba 116019"],"award-info":[{"award-number":["N\u00ba 116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["N\u00ba 116019"],"award-info":[{"award-number":["N\u00ba 116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["N\u00ba 116019"],"award-info":[{"award-number":["N\u00ba 116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["N\u00ba 116019"],"award-info":[{"award-number":["N\u00ba 116019"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) frequently causes acute lower respiratory infection in children under 5, representing a high burden in Gavi-eligible countries\u00a0(mostly low-income and lower-middle-income). Since multiple RSV interventions, including vaccines and monoclonal antibody (mAb) candidates, are under development, we aim to evaluate the key drivers of the cost-effectiveness of maternal vaccination and infant mAb for 72 Gavi countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A static Multi-Country Model Application for RSV Cost-Effectiveness poLicy (MCMARCEL) was developed to follow RSV-related events monthly from birth until 5\u00a0years of age. MCMARCEL was parameterised using country- and age-specific demographic, epidemiological, and cost data. The interventions\u2019 level and duration of effectiveness were guided by the World Health Organization\u2019s preferred product characteristics and other literature. Maternal vaccination and mAb were assumed to require single-dose administration at prices assumed to align with other Gavi-subsidised technologies. The effectiveness and the prices of the interventions were simultaneously varied in extensive scenario analyses. Disability-adjusted life years (DALYs) were the primary health outcomes for cost-effectiveness, integrated with probabilistic sensitivity analyses\u00a0and Expected Value of Partially Perfect Information analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The RSV-associated disease burden among children in these 72 countries is estimated at an average of 20.8 million cases, 1.8 million hospital admissions, 40 thousand deaths, 1.2 million discounted DALYs, and US$611 million discounted direct costs. Strategy \u2018mAb\u2019 is more effective due to its assumed longer duration of protection versus maternal vaccination, but it was also assumed to be more expensive. Given all parameterised uncertainty, the optimal strategy of choice tends to change for increasing willingness to pay (WTP) values per DALY averted from the current situation to maternal vaccination (at WTP\u2009&gt;\u2009US$1000) to mAB (at WTP\u2009&gt;\u2009US$3500). The age-specific proportions of cases that are hospitalised and\/or die cause most of the uncertainty in the choice of optimal strategy. Results are broadly similar across countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both the maternal and mAb strategies need to be competitively priced to be judged as relatively cost-effective. Information on the level and duration of protection is crucial, but also more and better disease burden evidence\u2014especially on RSV-attributable hospitalisation and death rates\u2014is needed to support policy choices when novel RSV products become available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-020-01537-6","type":"journal-article","created":{"date-parts":[[2020,4,5]],"date-time":"2020-04-05T22:02:36Z","timestamp":1586124156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5\u00a0years in 72 Gavi-eligible countries"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-1791","authenticated-orcid":false,"given":"Xiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Antillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Bilcke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"issue":"9725","key":"1537_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545\u201355.","journal-title":"Lancet"},{"issue":"10098","key":"1537_CR2","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/S0140-6736(17)30938-8","volume":"390","author":"T Shi","year":"2017","unstructured":"Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946\u201358.","journal-title":"Lancet"},{"issue":"2","key":"1537_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1542\/peds.2014-1665","volume":"134","author":"American Academy of Pediatrics Committee On Infectious D, American Academy Of Pediatrics Bronchiolitis Guidelines C","year":"2014","unstructured":"American Academy of Pediatrics Committee On Infectious D, American Academy Of Pediatrics Bronchiolitis Guidelines C. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415\u201320.","journal-title":"Pediatrics"},{"issue":"2","key":"1537_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.vaccine.2015.05.093","volume":"34","author":"K Modjarrad","year":"2016","unstructured":"Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, Group WRVCE. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine. 2016;34(2):190\u20137.","journal-title":"Vaccine"},{"key":"1537_CR5","volume-title":"A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization [NCT02624947]","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov: A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization [NCT02624947]. 2018."},{"key":"1537_CR6","unstructured":"Novavax: Novavax announces topline results from phase 3 PrepareTM Trial of ResVax\u2122 for prevention of RSV disease in infants via maternal immunization. In. Novavax website (http:\/\/ir.novavax.com\/news-releases\/news-release-details\/novavax-announces-topline-results-phase-3-preparetm-trial); 2019. Accessed 28 Feb 2019."},{"key":"1537_CR7","unstructured":"ClinicalTrials.gov: A study to evaluate the safety and efficacy of MEDI8897 for the prevention of medically attended RSV LRTI in healthy preterm infants. In., vol. 2019; 2018."},{"key":"1537_CR8","unstructured":"AstraZeneca: EMA grants PRIME eligibility for potential next-generation RSV medicine MEDI8897. In. AstraZeneca Websites (https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/ema-grants-prime-eligibility-for-potential-next-generation-rsv-medicine-medi8897-05022019.html); 2019. Accessed 5 Feb 2019."},{"issue":"13","key":"1537_CR9","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1056\/NEJMra1509044","volume":"376","author":"SB Omer","year":"2017","unstructured":"Omer SB. Maternal immunization. N Engl J Med. 2017;376(13):1256\u201367.","journal-title":"N Engl J Med"},{"key":"1537_CR10","volume-title":"New guidelines on antenatal care for a positive pregnancy experience","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. New guidelines on antenatal care for a positive pregnancy experience. Geneva: World Health Organization; 2016."},{"key":"1537_CR11","unstructured":"Gavi Board starts framing Alliance\u2019s approach to 2021-2025 period [https:\/\/www.gavi.org\/library\/news\/press-releases\/2018\/gavi-board-starts-framing-alliance-s-approach-to-2021-2025-period\/]. Accessed 12 May 2019."},{"issue":"8","key":"1537_CR12","doi-asserted-by":"publisher","first-page":"e367","DOI":"10.1016\/S2468-2667(17)30103-2","volume":"2","author":"D Cromer","year":"2017","unstructured":"Cromer D, van Hoek AJ, Newall AT, Pollard AJ, Jit M. Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health. 2017;2(8):e367\u201374.","journal-title":"Lancet Public Health"},{"key":"1537_CR13","volume-title":"World Population Prospects: The 2017 Revision","author":"United Nations; Population Division; Department of Economic and Social Affairs","year":"2017","unstructured":"United Nations; Population Division; Department of Economic and Social Affairs: World Population Prospects: The 2017 Revision. 2017."},{"issue":"10018","key":"1537_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0140-6736(15)00837-5","volume":"387","author":"JE Lawn","year":"2016","unstructured":"Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, Flenady V, Froen JF, Qureshi ZU, Calderwood C, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387(10018):587\u2013603.","journal-title":"Lancet"},{"key":"1537_CR15","unstructured":"World Health Organization. WHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines. Geneva: World Health Organization; 2017. Licence: CC BY-NCSA 3.0 IGO."},{"key":"1537_CR16","unstructured":"World Health Organization: Global health Observatory. In. http:\/\/apps.who.int\/gho\/data\/node.imr.WHS4_106?lang=en; 2018. Accessed 5 Feb 2019."},{"issue":"1","key":"1537_CR17","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.06.010408","volume":"6","author":"S Zhang","year":"2016","unstructured":"Zhang S, Sammon PM, King I, Andrade AL, Toscano CM, Araujo SN, Sinha A, Madhi SA, Khandaker G, Yin JK, et al. Cost of management of severe pneumonia in young children: systematic analysis. J Glob Health. 2016;6(1):010408.","journal-title":"J Glob Health"},{"key":"1537_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-018-0095-x","volume":"16","author":"K Stenberg","year":"2018","unstructured":"Stenberg K, Lauer JA, Gkountouras G, Fitzpatrick C, Stanciole A. Econometric estimation of WHO-CHOICE country-specific costs for inpatient and outpatient health service delivery. Cost Eff Resour Alloc. 2018;16:11.","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"1537_CR19","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1017\/S0950268814001393","volume":"143","author":"PK Munywoki","year":"2015","unstructured":"Munywoki PK, Koech DC, Agoti CN, Kibirige N, Kipkoech J, Cane PA, Medley GF, Nokes DJ. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Infect. 2015;143(4):804\u201312.","journal-title":"Epidemiol Infect"},{"issue":"9859","key":"1537_CR20","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","volume":"380","author":"JA Salomon","year":"2012","unstructured":"Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129\u201343.","journal-title":"Lancet"},{"issue":"2","key":"1537_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032056","volume":"7","author":"N Homaira","year":"2012","unstructured":"Homaira N, Luby SP, Petri WA, Vainionpaa R, Rahman M, Hossain K, Snider CB, Rahman M, Alamgir AS, Zesmin F, et al. Incidence of respiratory virus-associated pneumonia in urban poor young children of Dhaka, Bangladesh, 2009-2011. PLoS One. 2012;7(2):e32056.","journal-title":"PLoS One"},{"issue":"1","key":"1537_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1086\/524019","volume":"46","author":"DJ Nokes","year":"2008","unstructured":"Nokes DJ, Okiro EA, Ngama M, Ochola R, White LJ, Scott PD, English M, Cane PA, Medley GF. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya. Clin Infect Dis. 2008;46(1):50\u20137.","journal-title":"Clin Infect Dis"},{"key":"1537_CR23","unstructured":"Zhang S. Cost of RSV-associated ALRI management in young children at the regional and global level - A systematic review and meta-analysis. The Journal of Infectious Diseases. JID-67577."},{"key":"1537_CR24","unstructured":"World Bank. World Bank Open Data: Consumer price index, The World Bank Group; 2016 Weblink: https:\/\/data.worldbank.org\/. Accessed 28 Nov 2017."},{"issue":"45","key":"1537_CR25","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1016\/j.vaccine.2017.09.043","volume":"35","author":"AB Hogan","year":"2017","unstructured":"Hogan AB, Campbell PT, Blyth CC, Lim FJ, Fathima P, Davis S, Moore HC, Glass K. Potential impact of a maternal vaccine for RSV: a mathematical modelling study. Vaccine. 2017;35(45):6172\u20139.","journal-title":"Vaccine"},{"key":"1537_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12916-015-0283-x","volume":"13","author":"P Poletti","year":"2015","unstructured":"Poletti P, Merler S, Ajelli M, Manfredi P, Munywoki PK, Nokes D, Melegaro A. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings. BMC Med. 2015;13:49.","journal-title":"BMC Med"},{"key":"1537_CR27","unstructured":"UNICEF vaccine price information [https:\/\/www.who.int\/immunization\/programmes_systems\/procurement\/v3p\/platform\/module3\/price_information\/en\/index2.html]. Accessed 25 Aug 2019."},{"key":"1537_CR28","unstructured":"World Health Organization: Monitoring vaccine wastage at country level : guidelines for programme managers. In. Edited by Immunization Vaccines and Biologicals. Geneva: World Health Organization; 2005."},{"key":"1537_CR29","doi-asserted-by":"crossref","unstructured":"Briggs AC, K. Sculpher, M: Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.","DOI":"10.1093\/oso\/9780198526629.001.0001"},{"key":"1537_CR30","doi-asserted-by":"publisher","unstructured":"Multi-Country Model Application for RSV Cost-Effectiveness Policy (McMarcel). [https:\/\/doi.org\/10.5281\/zenodo.3663447]. Accessed 13 Feb 2020.","DOI":"10.5281\/zenodo.3663447"},{"key":"1537_CR31","unstructured":"06a -Annex C: Respiratory Syncytial Virus Investment Case [https:\/\/www.gavi.org\/library\/gavi-documents\/strategy\/ppc-meeting-18-19-october-2018%2D%2D-vis-06a%2D%2D-annex-c%2D%2Drespiratory-syncytial-virus-investment-case\/]. Accessed 30 Sept 2019."},{"key":"1537_CR32","doi-asserted-by":"crossref","unstructured":"Swamy GK: Safety of third trimester immunization with a respiratory syncytial virus (RSV) F protein vaccine and protection of infants over the first 180 days of life against all-cause lower respiratory tract infection. In. Novavax website (https:\/\/novavax.com\/download\/files\/20190808-IDSOG-Presentation.pdf); 2019. Accessed 30 Aug 2019.","DOI":"10.1016\/j.ajog.2019.10.081"},{"issue":"9","key":"1537_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138018","volume":"10","author":"TM Kinyanjui","year":"2015","unstructured":"Kinyanjui TM, House TA, Kiti MC, Cane PA, Nokes DJ, Medley GF. Vaccine induced herd immunity for control of respiratory syncytial virus disease in a low-income country setting. PLoS One. 2015;10(9):e0138018.","journal-title":"PLoS One"},{"issue":"32","key":"1537_CR34","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1016\/j.vaccine.2008.04.053","volume":"26","author":"SJ Goldie","year":"2008","unstructured":"Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26(32):4080\u201393.","journal-title":"Vaccine"},{"issue":"46","key":"1537_CR35","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.1016\/j.vaccine.2017.09.048","volume":"35","author":"BD Gessner","year":"2017","unstructured":"Gessner BD, Kaslow D, Louis J, Neuzil K, O'Brien KL, Picot V, Pang T, Parashar UD, Saadatian-Elahi M, Nelson CB. Estimating the full public health value of vaccination. Vaccine. 2017;35(46):6255\u201363.","journal-title":"Vaccine"},{"issue":"12","key":"1537_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny MP, Hill SR. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925\u201330.","journal-title":"Bull World Health Organ"},{"issue":"8","key":"1537_CR37","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/hec.625","volume":"10","author":"P Beutels","year":"2001","unstructured":"Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ. 2001;10(8):751\u201374.","journal-title":"Health Econ"},{"key":"1537_CR38","unstructured":"World Health Organization. Summary of the pertussis vaccines. Summary of the Pertussis Vaccines: WHO position paper\u2013 August 2015, WHO weekly epidemiological record. Geneva; 2015. Weblink: https:\/\/www.who.int\/wer\/2015\/wer9035.pdf?ua=1. Accessed 05 Feb 2019."},{"issue":"7","key":"1537_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30232-7","volume":"6","author":"NM Scheltema","year":"2018","unstructured":"Scheltema NM, Nibbelke EE, Pouw J, Blanken MO, Rovers MM, Naaktgeboren CA, Mazur NI, Wildenbeest JG, van der Ent CK, Bont LJ. RSV prevention in infancy and asthma in later life - Authors' reply. Lancet Respir Med. 2018;6(7):e33.","journal-title":"Lancet Respir Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01537-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-020-01537-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01537-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T08:52:39Z","timestamp":1722675159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01537-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1537"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01537-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This article is the result of work conducted independently by the authors. As part of standard procedures of the Innovative Medicines Initiative (IMI) project, all academic and EFPIA members of the Respiratory Syncytial Virus Consortium in Europe (RESCEU) steering committee were given the opportunity to comment on this manuscript prior to submission. In RESCEU\u2019s steering committee, employees of five pharmaceutical companies (Novavax, Sanofi Pasteur, GSK, Pfizer, and Johnson & Johnson) take representation for EFPIA. While the pharmaceutical companies were allowed to read and comment on the manuscript, they did not influence the final decision to publish nor did they have control over the contents of the publication.This entire manuscript and the additional file are written independently by the authors. None of the authors have received any forms of pecuniary or other support from the pharmaceutical industry.PB declares that a part-time (35%) university chair (occupied by Niel Hens) in the Centre for Health Economics Research and Modelling Infectious Diseases at the University of Antwerp was partially supported in 2009\u20132018 by a recurring gift from Pfizer, and this chair has also been partially supported by GSK in 2017.The University of Antwerp also received compensation for PB and LW\u2019s attendance at two meetings of a Belgian advisory board on economic evaluations of vaccines convened by Pfizer in 2019, outside of this submission work. The clinical trials centre (to which none of the authors belong) at the University of Antwerp conducts numerous vaccine trials and epidemiological studies for vaccine developers and other stakeholders in global public health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}